<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169418">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00891228</url>
  </required_header>
  <id_info>
    <org_study_id>HSN275200800042U</org_study_id>
    <nct_id>NCT00891228</nct_id>
  </id_info>
  <brief_title>Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men</brief_title>
  <acronym>CCN007</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind Comparator Trial of the Safety and Sperm and Gonadotropin Suppression Resulting From Combined Use of Nestorone® Gel (0, 8 or 12 mg NES) and Testosterone Gel (10 g) Compared With Testosterone Gel in Normal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Population Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the number of men who have suppression of sperm production when using a daily
      regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the number of men who have suppression of sperm production ≤1 million/mL when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the number of men who have suppression of sperm production ≤ 3 million/mL or azoospermia when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel.</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the level of suppression of gonadotropins caused by transdermal usage of Testosterone Gel and 0, 8, or 12 mg Nestorone® Gel and to correlate the level of gonadotropin suppression with sperm suppression.</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact on sperm morphology and motility in men who are not azoospermic.</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 0 mg per day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 8 mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.</description>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 0 mg per day</arm_group_label>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 8 mg per day</arm_group_label>
    <arm_group_label>Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nestorone®</intervention_name>
    <description>Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.</description>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 8 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nestorone®</intervention_name>
    <description>Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.</description>
    <arm_group_label>Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nestorone®</intervention_name>
    <description>Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.</description>
    <arm_group_label>Testosterone Gel 10 g and Nestorone® 0 mg per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Men who meet all the following criteria are eligible for enrollment in the trial:

          1. Male volunteers in good health as confirmed by physical examination, medical history,
             and clinical laboratory tests of blood and urine at the time of screening

          2. 18 to 50 years of age

          3. BMI ≤ 33 calculated as weight in Kg/ (height in cm) 2

          4. No history of hormonal therapy use in the last six months prior to the first
             screening visit

          5. Subject will agree to use a recognized effective method of contraception with his
             partner (i.e. at a minimum, use double-barrier contraception) during the course of
             the study treatment and recovery phase

          6. In the opinion of the investigator, subject is able to comply with the protocol,
             understand and sign an informed consent and HIPAA form

          7. Does not meet any of the exclusion criteria.

        Exclusion Criteria:

        Men who meet any of the following criteria are NOT eligible for enrollment in the trial:

          1. Men participating in another clinical trial involving an investigational drug within
             the last 30 days prior to the first screening visit

          2. Men not living in the catchment's area of the clinic or within a reasonable distance
             from the site

          3. Clinically significant abnormal findings at screening

          4. Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values

          5. Abnormal serum chemistry values, according to local laboratory normal values that
             indicate liver or kidney dysfunction or that may be considered clinically
             significant. Other abnormal lab values may also be exclusionary, at the discretion of
             the investigator

          6. Sperm concentration below 15 million/mL in more than one of three screening samples

          7. Use of androgens or body building substances within 6 months before first screening
             visit

          8. Diastolic (D) blood pressure (BP) ≥ 85 and Systolic (S) BP ≥ 135 mm Hg; (BP will be
             taken 3 times at 5 minute intervals and the mean of all measurements be considered)

          9. History of hypertension, including hypertension controlled with treatment

         10. Known history of primary testicular disease or disorders of the
             hypothalamic-pituitary axis

         11. Known hypersensitivity to progestins

         12. Family or personal history of venous thromboembolism

         13. Benign or malignant liver tumors; active liver disease

         14. History of breast carcinoma

         15. Known history of reproductive dysfunction including vasectomy or infertility

         16. Known history of cardiac, renal, hepatic or prostatic disease

         17. A serious systemic disease such as diabetes mellitus or morbid obesity (body weight
             greater than 120% of ideal body weight or BMI limitation as above)

         18. History of sleep apnea

         19. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation
             of steroid hormones and study treatment compliance

         20. Known dermatitis or severe skin disorder

         21. Partner is known to be pregnant

         22. Men desiring fertility within the first 24 weeks of study participation.

        Men participating in competitive sports where drug screening for prohibited substances
        (including anabolic steroids) is routine will be advised of the relative and temporary
        hazards that participating in this study may have for their fertility or sporting status.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LA BioMedical Research Institute, Harbor-UCLA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Bremner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor-UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>December 14, 2012</lastchanged_date>
  <firstreceived_date>April 30, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Male Contraception</keyword>
  <keyword>Suppression of Sperm Production</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>ST 1435</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
